A mammalian functional-genetic approach to characterizing cancer therapeutics

Nature Chemical Biology

Volumn 7, Issue 2, 2011, Pages 92-100

  Jiang, Hai ^a   Pritchard, Justin R ^a   Williams, Richard T ^b   Lauffenburger, Douglas A ^a,c   Hemann, Michael T ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c Massachusetts Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 METHOXYESTRADIOL; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BIIB 021; BUSULFAN; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CY 190602; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; SHORT HAIRPIN RNA; TEMOZOLOMIDE; THIOTEPA; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VER 50589; VINBLASTINE; VINCRISTINE; ZEBULARINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE;

MAMMALIA;

EID: 78751567879     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.503     Document Type: Article

References (19)

1. Demeler, B. & van Holde, K.E. Sedimentation velocity analysis of highly heterogeneous systems. Anal. Biochem. 335, 279-288 (2004).
2. McGinty, R.K. et al. Structure activity analysis of semisynthetic nucleosomes: Mechanistic insights into the stimulation of Dot1L by ubiquitylated histone H2B. ACS Chem. Biol. 4, 958-968 (2009).
3. Vijay-Kumar, S., Bugg, C.E. & Cook, W.J. Structure of ubiquitin refined at 1.8 A resolution. J. Mol. Biol. 194, 531-544 (1987).
4. Ramelot, T.A. et al. Solution structure of the yeast ubiquitin-like modifier protein Hub1. J. Struct. Funct. Genomics 4, 25-30 (2003).
5. Cimprich, K.A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616-627 (2008).
6. Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003).
7. Reinhardt, H.C., Aslanian, A.S., Lees, J.A. & Yaffe, M.B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175-189 (2007).
8. Pearce, A.K. & Humphrey, T.C. Integrating stress-response and cell-cycle checkpoint pathways. Trends Cell Biol. 11, 426-433 (2001).
9. Pritchard, J.R. et al. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol. Cancer Ther. 8, 2183-2192 (2009).
10. Swann, P.F. et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273, 1109-1111 (1996).
11. Mojas, N., Lopes, M. & Jiricny, J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev. 21, 3342-3355 (2007).
12. Akhtar, M.S. et al. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. Mol. Cell 34, 387-393 (2009).
13. Ljungman, M. & Paulsen, M.T. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 60, 785-789 (2001).
14. MacCallum, D.E. et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399-5407 (2005).
15. Lindemann, R.K. et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl. Acad. Sci. USA 104, 8071-8076 (2007).
16. Burgess, D.J. et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. USA 105, 9053-9058 (2008).
17. Williams, R.T., Roussel, M.F. & Sherr, C.J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 103, 6688-6693 (2006).
18. Dickins, R.A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289-1295 (2005).
19. Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).